Cargando…

HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients

BACKGROUND: Conflicting results have been reported regarding the predicative roles of alloreactive natural killer (NK) cells on the outcomes of transplantation in leukaemia patients. METHODS: We prospectively analysed the human leukocyte antigen (HLA) typing of donor–recipient pairs and the KIR typi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, X-Y, Chang, Y-J, Xu, L-P, Zhang, X-H, Liu, K-Y, Li, D, Huang, X-J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453853/ https://www.ncbi.nlm.nih.gov/pubmed/25077441 http://dx.doi.org/10.1038/bjc.2014.423

Ejemplares similares

T-cell-replete haploidentical stem cell transplantation is highly efficacious for relapsed and refractory childhood acute leukaemia
por: Kobayashi, S, et al.
Publicado: (2014)

Investigation of KIR/HLA relationship and other clinical variables after T-cell-replete haploidentical bone marrow transplantation in patients with acute myeloid leukemia (AML)
por: Bakhtiari, Tahereh, et al.
Publicado: (2023)

How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?
por: Chang, Ying-Jun, et al.
Publicado: (2016)

Non-Expressed Donor KIR3DL1 Alleles May Represent a Risk Factor for Relapse after T-Replete Haploidentical Hematopoietic Stem Cell Transplantation
por: Legrand, Nolwenn, et al.
Publicado: (2023)

Immune reconstitution after T-cell replete HLA haploidentical hematopoietic stem cell transplantation using high-dose post-transplant cyclophosphamide
por: Maeda, Yoshinobu
Publicado: (2021)

Efficient and accurate KIR and HLA genotyping with massively parallel sequencing data
por: Song, Li, et al.
Publicado: (2023)

T Cell-Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation for Treatment of T-Lymphoblastic Lymphoma
por: Guan, Lixun, et al.
Publicado: (2018)

Real‐world experience: Introduction of T cell replete haploidentical transplantations in a single center
por: van Gorkom, Gwendolyn, et al.
Publicado: (2021)

Brain toxoplasmosis after HLA haploidentical transplantation for acute myeloid leukemia
por: Tsushima, Takafumi, et al.
Publicado: (2022)

T-Cell-Replete Versus ex vivo T-Cell-Depleted Haploidentical Haematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukaemia and Other Haematological Malignancies
por: Kleinschmidt, Katharina, et al.
Publicado: (2021)

Effectiveness of T-Cell Replete Haploidentical Hematopoietic Stem Cell Transplantation for Refractory/Relapsed B Cell Acute Lymphoblastic Leukemia in Children and Adolescents
por: Sano, Hideki, et al.
Publicado: (2021)

T‐cell replete haploidentical stem cell transplantation with low dose anti‐thymocyte globulin for relapsed/refractory Ewing sarcoma family tumors
por: Sano, Hideki, et al.
Publicado: (2021)

Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide
por: Solomon, Scott R., et al.
Publicado: (2016)

Association of iKIR-mismatch model and donor aKIRs with better outcome in haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia
por: Zhang, Yu, et al.
Publicado: (2023)

Deciphering the biology of KIR2DL3(+) T lymphocytes that are associated to relapse in haploidentical HSCT
por: David, Gaëlle, et al.
Publicado: (2021)

HLA-Haploidentical Family Donors: The New Promise for Childhood Acute Lymphoblastic Leukaemia?
por: Ab Rahman, Syaza, et al.
Publicado: (2022)

Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy
por: Zou, Jun, et al.
Publicado: (2022)

Unfavourable clinical implications for HLA-G expression in acute myeloid leukaemia
por: Yan, W-H, et al.
Publicado: (2008)

Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation
por: Faridi, Rehan Mujeeb, et al.
Publicado: (2016)

Impact of Donor-Specific anti-HLA Antibodies and Donor KIR Characteristics in Haploidentical HSCT for Beta-Thalassemia
por: Andreani, Marco, et al.
Publicado: (2017)

Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation
por: Zhao, Yanmin, et al.
Publicado: (2021)

Assessment of Patient-Specific Human Leukocyte Antigen Genomic Loss at Relapse After Antithymocyte Globulin–Based T-Cell–Replete Haploidentical Hematopoietic Stem Cell Transplant
por: Wu, Hengwei, et al.
Publicado: (2022)

T-cell replete cord transplants give superior outcomes in high-risk and relapsed/refractory pediatric myeloid malignancy
por: Horgan, Claire, et al.
Publicado: (2023)

Stem cell collection in unmanipulated HLA-haploidentical/mismatched related transplantation with combined granulocyte-colony stimulating factor-mobilised blood and bone marrow for patients with haematologic malignancies: the impact of donor characteristics and procedural settings
por: Zhang, C, et al.
Publicado: (2010)

NK Cell Alloreactivity against KIR-Ligand-Mismatched HLA-Haploidentical Tissue Derived from HLA Haplotype-Homozygous iPSCs
por: Ichise, Hiroshi, et al.
Publicado: (2017)

A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies
por: Solh, Melhem M., et al.
Publicado: (2021)

Editorial: The Immunobiology of HLA-Haploidentical Hematopoietic Cell Transplantation
por: Mancusi, Antonella, et al.
Publicado: (2020)

Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report
por: Jin, Mengqi, et al.
Publicado: (2019)

Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation
por: McCurdy, Shannon R., et al.
Publicado: (2015)

PB2190: HLA-HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER REDUCED-INTENSITY CONDITIONING
por: Kim, J., et al.
Publicado: (2022)

Killer Immunoglobulin-like Receptor (KIR) and HLA Genotypes Affect the Outcome of Allogeneic Kidney Transplantation
por: Nowak, Izabela, et al.
Publicado: (2012)

P823: THE INCIDENCE, OUTCOMES, AND RISK FACTORS OF SECONDARY POOR GRAFT FUNCTION IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACQUIRED APLASTIC ANEMIA
por: lin, F., et al.
Publicado: (2022)

Correction to: Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report
por: Jin, Mengqi, et al.
Publicado: (2019)

Thymic function recovery after unrelated donor cord blood or T-cell depleted HLA-haploidentical stem cell transplantation correlates with leukemia relapse
por: Clave, Emmanuel, et al.
Publicado: (2013)

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
por: Munchel, Ashley, et al.
Publicado: (2011)

T-Cell Replete Myeloablative Haploidentical Bone Marrow Transplantation Is an Effective Option for Pediatric and Young Adult Patients With High-Risk Hematologic Malignancies
por: Katsanis, Emmanuel, et al.
Publicado: (2020)

CTLA-4 polymorphisms and haplotype correlate with survival in ALL after allogeneic stem cell transplantation from related HLA-haplotype-mismatched donor
por: Qin, X.-Y., et al.
Publicado: (2016)

A Phase I Trial of Allogeneic γδ T Lymphocytes From Haploidentical Donors in Patients With Refractory or Relapsed Acute Myeloid Leukemia
por: Vydra, Jan, et al.
Publicado: (2023)

Small but mighty: T-replete cords for myeloid disease
por: LaBelle, James L.
Publicado: (2023)

Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia
por: Thakar, Monica S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dpefdheva8q8mcf6dq8moaqaci